Cargando…

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer

The success of the PROfound, IPATential150, and TheraP trials promoted the transition from sequential treatment to therapeutic targets (TTs)‐guided precision treatment in metastatic castration‐resistant prostate cancer (mCRPC). The objective of this study was to evaluate the prevalence and prognosti...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Jian, Zhao, Jinou, Ni, Xudong, Gan, Hualei, Wei, Yu, Wu, Junlong, Zhang, Tingwei, Wang, Qifeng, Freedland, Stephen J., Wang, Beihe, Song, Shaoli, Ye, Dingwei, Liu, Chang, Zhu, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718110/
https://www.ncbi.nlm.nih.gov/pubmed/36209367
http://dx.doi.org/10.1002/1878-0261.13320
_version_ 1784843018014031872
author Pan, Jian
Zhao, Jinou
Ni, Xudong
Gan, Hualei
Wei, Yu
Wu, Junlong
Zhang, Tingwei
Wang, Qifeng
Freedland, Stephen J.
Wang, Beihe
Song, Shaoli
Ye, Dingwei
Liu, Chang
Zhu, Yao
author_facet Pan, Jian
Zhao, Jinou
Ni, Xudong
Gan, Hualei
Wei, Yu
Wu, Junlong
Zhang, Tingwei
Wang, Qifeng
Freedland, Stephen J.
Wang, Beihe
Song, Shaoli
Ye, Dingwei
Liu, Chang
Zhu, Yao
author_sort Pan, Jian
collection PubMed
description The success of the PROfound, IPATential150, and TheraP trials promoted the transition from sequential treatment to therapeutic targets (TTs)‐guided precision treatment in metastatic castration‐resistant prostate cancer (mCRPC). The objective of this study was to evaluate the prevalence and prognostic value of TTs from these three trials. All included Chinese mCRPC patients underwent circulating tumor DNA (ctDNA) sequencing, PTEN status assessment, and dual‐tracer [(68)Ga‐prostate‐specific membrane antigen (PSMA) and (18)F‐fluorodexyglucose (FDG)] positron emission tomography/computed tomography (PET/CT). Previous treatment with cabazitaxel, Lu‐PSMA or olaparib was unallowed. Patients with known significant sarcomatoid or spindle cell or neuroendocrine small cell components were also excluded. TTs were defined as positive as follows: (a) high PSMA and no PSMA−/FDG+ disease on dual‐tracer PET/CT scans; (b) defects in homologous recombination repair (HRR) genes in ctDNA; and (c) loss of PTEN immunohistochemistry staining in tumor tissue. The prevalence and prognostic value on progression‐free survival (PFS) of TTs were evaluated. A total of 106 consecutive mCRPC patients were included. The prevalence of positive PET/CT, HRR defect, and PTEN loss was 30%, 29% and 16%, respectively. Sixty‐three patients had at least one TT. Metastatic volume (odds ratio = 5.0; P = 0.017) was the only independent factor of positive TT in multivariate analysis. Seventy‐four patients received abiraterone after TT screening. Patients with positive PET/CT (P = 0.011) and HRR defect (P = 0.002) had a significantly shorter PFS after receiving abiraterone than patients with negative TTs. However, PTEN status was unrelated to PFS, which may be due to a less number of patients with PTEN loss (P = 0.952). Overall, patients with any positive TTs had a significantly shorter PFS after abiraterone than patients with negative TTs (P = 0.009). Nearly 60% of Chinese patients with mCRPC who had a poor prognosis on abiraterone were candidates for precision treatments based on the specific criteria of TTs.
format Online
Article
Text
id pubmed-9718110
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97181102022-12-05 The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer Pan, Jian Zhao, Jinou Ni, Xudong Gan, Hualei Wei, Yu Wu, Junlong Zhang, Tingwei Wang, Qifeng Freedland, Stephen J. Wang, Beihe Song, Shaoli Ye, Dingwei Liu, Chang Zhu, Yao Mol Oncol Research Articles The success of the PROfound, IPATential150, and TheraP trials promoted the transition from sequential treatment to therapeutic targets (TTs)‐guided precision treatment in metastatic castration‐resistant prostate cancer (mCRPC). The objective of this study was to evaluate the prevalence and prognostic value of TTs from these three trials. All included Chinese mCRPC patients underwent circulating tumor DNA (ctDNA) sequencing, PTEN status assessment, and dual‐tracer [(68)Ga‐prostate‐specific membrane antigen (PSMA) and (18)F‐fluorodexyglucose (FDG)] positron emission tomography/computed tomography (PET/CT). Previous treatment with cabazitaxel, Lu‐PSMA or olaparib was unallowed. Patients with known significant sarcomatoid or spindle cell or neuroendocrine small cell components were also excluded. TTs were defined as positive as follows: (a) high PSMA and no PSMA−/FDG+ disease on dual‐tracer PET/CT scans; (b) defects in homologous recombination repair (HRR) genes in ctDNA; and (c) loss of PTEN immunohistochemistry staining in tumor tissue. The prevalence and prognostic value on progression‐free survival (PFS) of TTs were evaluated. A total of 106 consecutive mCRPC patients were included. The prevalence of positive PET/CT, HRR defect, and PTEN loss was 30%, 29% and 16%, respectively. Sixty‐three patients had at least one TT. Metastatic volume (odds ratio = 5.0; P = 0.017) was the only independent factor of positive TT in multivariate analysis. Seventy‐four patients received abiraterone after TT screening. Patients with positive PET/CT (P = 0.011) and HRR defect (P = 0.002) had a significantly shorter PFS after receiving abiraterone than patients with negative TTs. However, PTEN status was unrelated to PFS, which may be due to a less number of patients with PTEN loss (P = 0.952). Overall, patients with any positive TTs had a significantly shorter PFS after abiraterone than patients with negative TTs (P = 0.009). Nearly 60% of Chinese patients with mCRPC who had a poor prognosis on abiraterone were candidates for precision treatments based on the specific criteria of TTs. John Wiley and Sons Inc. 2022-10-20 2022-12 /pmc/articles/PMC9718110/ /pubmed/36209367 http://dx.doi.org/10.1002/1878-0261.13320 Text en © 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Pan, Jian
Zhao, Jinou
Ni, Xudong
Gan, Hualei
Wei, Yu
Wu, Junlong
Zhang, Tingwei
Wang, Qifeng
Freedland, Stephen J.
Wang, Beihe
Song, Shaoli
Ye, Dingwei
Liu, Chang
Zhu, Yao
The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
title The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
title_full The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
title_fullStr The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
title_full_unstemmed The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
title_short The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
title_sort prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718110/
https://www.ncbi.nlm.nih.gov/pubmed/36209367
http://dx.doi.org/10.1002/1878-0261.13320
work_keys_str_mv AT panjian theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT zhaojinou theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT nixudong theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT ganhualei theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT weiyu theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT wujunlong theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT zhangtingwei theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT wangqifeng theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT freedlandstephenj theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT wangbeihe theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT songshaoli theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT yedingwei theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT liuchang theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT zhuyao theprevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT panjian prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT zhaojinou prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT nixudong prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT ganhualei prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT weiyu prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT wujunlong prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT zhangtingwei prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT wangqifeng prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT freedlandstephenj prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT wangbeihe prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT songshaoli prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT yedingwei prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT liuchang prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer
AT zhuyao prevalenceandprognosisofnextgenerationtherapeutictargetsinmetastaticcastrationresistantprostatecancer